Download PDF
Semin Neurol 2016; 36(02): 212-218
DOI: 10.1055/s-0035-1571212
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Voiding Dysfunction in Multiple Sclerosis

Anton Wintner   *
1   Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
,
Michelle M. Kim   *
1   Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
,
Seth K. Bechis   *
1   Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
,
Evgeniy I. Kreydin
2   Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California
› Author Affiliations
Further Information

Publication History

Publication Date:
26 April 2016 (online)

    Permissions and Reprints

Corrected by:

Voiding Dysfunction in Multiple SclerosisSemin Neurol 2016; 36(02): 219-220
DOI: 10.1055/s-0036-1582255

Abstract

Voiding dysfunction is a common and debilitating consequence of multiple sclerosis (MS). The prevalence and severity of voiding dysfunction increases with the increasing severity of MS, but even the mildest forms of the disease are associated with urinary symptoms in 30% of patients. Every component of the central nervous system is involved in regulating voiding; as a result, MS can lead to a wide variety of urinary symptoms and urologic complications. The effect of MS on voiding can be classified according to the resulting function of the bladder and the urethral sphincter during storage and emptying of urine. Therapy is targeted to the specific bladder and sphincter abnormalities that occur. The primary goals of therapy are prevention of injury to the upper urinary tract (kidneys), reduction in urinary tract infections, and maintenance of urinary continence. These goals can be achieved by interventions ranging from behavioral modification to major reconstructive surgery.

Keywords

neurogenic bladder - voiding dysfunction - multiple sclerosis

* These authors contributed equally to this publication.


 

  • References

  • 1 de Sèze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B ; GENULF. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 2007; 13 (7) 915-928
    CrossrefPubMedGoogle Scholar
  • 2 Fowler CJ, Panicker JN, Drake M , et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009; 80 (5) 470-477
    Google Scholar
  • 3 Tapia CI, Khalaf K, Berenson K, Globe D, Chancellor M, Carr LK. Health-related quality of life and economic impact of urinary incontinence due to detrusor overactivity associated with a neurologic condition: a systematic review. Health Qual Life Outcomes 2013; 11: 13
    CrossrefPubMedGoogle Scholar
  • 4 Quarto G, Autorino R, Gallo A , et al. Quality of life in women with multiple sclerosis and overactive bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18 (2) 189-194
    CrossrefPubMedGoogle Scholar
  • 5 Thom DH, Nygaard IE, Calhoun EA. Urologic diseases in America project: urinary incontinence in women-national trends in hospitalizations, office visits, treatment and economic impact. J Urol 2005; 173 (4) 1295-1301
    CrossrefPubMedGoogle Scholar
  • 6 Griffiths DJ, Fowler CJ. The micturition switch and its forebrain influences. Acta Physiol (Oxf) 2013; 207 (1) 93-109
    CrossrefPubMedGoogle Scholar
  • 7 Holstege G. Descending motor pathways and the spinal motor system: limbic and non-limbic components. Prog Brain Res 1991; 87: 307-421
    PubMedGoogle Scholar
  • 8 Holstege G. The emotional motor system in relation to the supraspinal control of micturition and mating behavior. Behav Brain Res 1998; 92 (2) 103-109
    CrossrefPubMedGoogle Scholar
  • 9 Mantyh PW. Forebrain projections to the periaqueductal gray in the monkey, with observations in the cat and rat. J Comp Neurol 1982; 206 (2) 146-158
    CrossrefPubMedGoogle Scholar
  • 10 Holstege G, Griffiths D, de Wall H, Dalm E. Anatomical and physiological observations on supraspinal control of bladder and urethral sphincter muscles in the cat. J Comp Neurol 1986; 250 (4) 449-461
    CrossrefPubMedGoogle Scholar
  • 11 Blok BF, Holstege G. Two pontine micturition centers in the cat are not interconnected directly: implications for the central organization of micturition. J Comp Neurol 1999; 403 (2) 209-218
    CrossrefPubMedGoogle Scholar
  • 12 de Groat WC, Wickens C. Organization of the neural switching circuitry underlying reflex micturition. Acta Physiol (Oxf) 2013; 207 (1) 66-84
    CrossrefPubMedGoogle Scholar
  • 13 Wein AJ. Pathophysiology and classification of lower urinary tract dysfunction: overview. In: A.J. Wein et al, eds. Campbell-Walsh Urology. Philadelphia, PA: Elsevier Saunders; 2012: 1834-1846
    CrossrefGoogle Scholar
  • 14 Yang CC. Bladder management in multiple sclerosis. Phys Med Rehabil Clin N Am 2013; 24 (4) 673-686
    CrossrefPubMedGoogle Scholar
  • 15 Wein AJ, Dmochowski RR. Neuromuscular dysfunction of the lower urinary tract. In: A.J. Wein et al, eds. Campbell-Walsh Urology. Philadelphia, PA: Elsevier Saunders; 2012: 1909-1946
    CrossrefGoogle Scholar
  • 16 De Ridder D, Vermeulen C, De Smet E, Van Poppel H, Ketelaer P, Baert L. Clinical assessment of pelvic floor dysfunction in multiple sclerosis: urodynamic and neurological correlates. Neurourol Urodyn 1998; 17 (5) 537-542
    CrossrefPubMedGoogle Scholar
  • 17 Litwiller SE, Frohman EM, Zimmern PE. Multiple sclerosis and the urologist. J Urol 1999; 161 (3) 743-757
    CrossrefPubMedGoogle Scholar
  • 18 McGuire EJ, Cespedes RD, O'Connell HE. Leak-point pressures. Urol Clin North Am 1996; 23 (2) 253-262
    CrossrefPubMedGoogle Scholar
  • 19 Araki I, Matsui M, Ozawa K, Takeda M, Kuno S. Relationship of bladder dysfunction to lesion site in multiple sclerosis. J Urol 2003; 169 (4) 1384-1387
    CrossrefPubMedGoogle Scholar
  • 20 Giannantoni A, Scivoletto G, Di Stasi SM, Grasso MG, Vespasiani G, Castellano V. Urological dysfunctions and upper urinary tract involvement in multiple sclerosis patients. Neurourol Urodyn 1998; 17 (2) 89-98
    CrossrefPubMedGoogle Scholar
  • 21 Betts CD, D'Mellow MT, Fowler CJ. Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry 1993; 56 (3) 245-250
    CrossrefPubMedGoogle Scholar
  • 22 Giannantoni A, Scivoletto G, Di Stasi SM , et al. Lower urinary tract dysfunction and disability status in patients with multiple sclerosis. Arch Phys Med Rehabil 1999; 80 (4) 437-441
    CrossrefPubMedGoogle Scholar
  • 23 De Ridder D, van Poppel H, Demonty L , et al. Bladder cancer in patients with multiple sclerosis treated with cyclophosphamide. J Urol 1998; 159 (6) 1881-1884
    CrossrefPubMedGoogle Scholar
  • 24 Blaivas JG, Barbalias GA. Detrusor-external sphincter dyssynergia in men with multiple sclerosis: an ominous urologic condition. J Urol 1984; 131 (1) 91-94
    PubMedGoogle Scholar
  • 25 de Sèze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B ; GENULF. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 2007; 13 (7) 915-928
    CrossrefPubMedGoogle Scholar
  • 26 Kim YH, Goodman C, Omessi E, Rivera V, Kattan MW, Boone TB. The correlation of urodynamic findings with cranial magnetic resonance imaging findings in multiple sclerosis. J Urol 1998; 159 (3) 972-976
    CrossrefPubMedGoogle Scholar
  • 27 McGuire EJ, Savastano JA. Urodynamic findings and long-term outcome management of patients with multiple sclerosis-induced lower urinary tract dysfunction. J Urol 1984; 132 (4) 713-715
    PubMedGoogle Scholar
  • 28 Pozzilli C, Grasso MG, Bastianello S , et al. Structural brain correlates of neurologic abnormalities in multiple sclerosis. Eur Neurol 1992; 32 (4) 228-230
    CrossrefPubMedGoogle Scholar
  • 29 Andrews KL, Husmann DA. Bladder dysfunction and management in multiple sclerosis. Mayo Clin Proc 1997; 72 (12) 1176-1183
    CrossrefPubMedGoogle Scholar
  • 30 Blaivas JG, Kaplan SA. Urologic dysfunction in patients with multiple sclerosis. Semin Neurol 1988; 8 (2) 159-165
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Davis R, Jones JS, Barocas DA , et al; American Urological Association. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol 2012; 188 (6, Suppl) 2473-2481
    CrossrefPubMedGoogle Scholar
  • 32 Esteve J, Kricker A, Ferlay J, Parkin D. Cancer, Facts and figures of cancer in the European Community. Lyon, France: International Agency for Research on Cancer; 1993
    Google Scholar
  • 33 Gallien P, Nicolas B, Robineau S , et al. Urological complications in multiple sclerosis: study of risk factors. Ann Readapt Med Phys 1998; 41 (3) 155-158 . DOI:10.1016/S0168-6054(98)80014-7
    CrossrefPubMedGoogle Scholar
  • 34 Amarenco G, Bosc S, Boiteau F. Les complications urologiques de la sclérose en plaques. 180 cas [Urologic complications of multiple sclerosis. 180 cases]. Presse Med 1996; 25 (22) 1007-1010
    PubMedGoogle Scholar
  • 35 Mahajan ST, Patel PB, Marrie RA. Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry. J Urol 2010; 183 (4) 1432-1437
    Google Scholar
  • 36 Klarskov P, Heely E, Nyholdt I, Rottensten K, Nordenbo A. Biofeedback treatment of bladder dysfunction in multiple sclerosis. A randomized trial. Scand J Urol Nephrol Suppl 1994; 157: 61-65
    PubMedGoogle Scholar
  • 37 Sand PK, Sand RI. The diagnosis and management of lower urinary tract symptoms in multiple sclerosis patients. Dis Mon 2013; 59 (7) 261-268
    CrossrefPubMedGoogle Scholar
  • 38 Bragg R, Hebel D, Vouri SM, Pitlick JM. Mirabegron: a Beta-3 agonist for overactive bladder. Consult Pharm 2014; 29 (12) 823-837
    CrossrefPubMedGoogle Scholar
  • 39 Sanford M. OnabotulinumtoxinA (Botox®): a review of its use in the treatment of urinary incontinence in patients with multiple sclerosis or subcervical spinal cord injury. Drugs 2014; 74 (14) 1659-1672
    CrossrefPubMedGoogle Scholar
  • 40 Kilicarslan H, Ayan S, Vuruskan H, Gokce G, Gultekin EY. Treatment of detrusor sphincter dyssynergia with baclofen and doxazosin. Int Urol Nephrol 2006; 38 (3–4) 537-541
    PubMedGoogle Scholar
  • 41 Bushman W, Steers WD, Meythaler JM. Voiding dysfunction in patients with spastic paraplegia: urodynamic evaluation and response to continuous intrathecal baclofen. Neurourol Urodyn 1993; 12 (2) 163-170
    CrossrefPubMedGoogle Scholar
  • 42 Denys P, Thiry-Escudie I, Ayoub N, Even-Schneider A, Benyahya S, Chartier-Kastler E. Urethral stent for the treatment of detrusor-sphincter dyssynergia: evaluation of the clinical, urodynamic, endoscopic and radiological efficacy after more than 1 year. J Urol 2004; 172 (2) 605-607
    CrossrefPubMedGoogle Scholar
  • 43 Mehta S, Hill D, Foley N , et al; Spinal Cord Injury Rehabilitation Evidence Research Team. A meta-analysis of botulinum toxin sphincteric injections in the treatment of incomplete voiding after spinal cord injury. Arch Phys Med Rehabil 2012; 93 (4) 597-603
    CrossrefPubMedGoogle Scholar
  • 44 Karsenty G, Baazeem A, Elzayat E, Corcos J. Injection of botulinum toxin type A in the urethral sphincter to treat lower urinary tract dysfunction: a review of indications, techniques and results. Can J Urol 2006; 13 (2) 3027-3033
    PubMedGoogle Scholar
  • 45 Gomelsky A, Coco CT, Dmochowski RR. Urinary incontinence in women: non-pharmacologic approaches and newer pharmacotherapies. Minerva Med 2014; 105 (4) 263-274
    PubMedGoogle Scholar
  • 46 Ghezzi A, Carone R, Del Popolo G , et al; Multiple Sclerosis Study Group, Italian Society of Neurology. Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group. Neurol Sci 2011; 32 (6) 1223-1231
    CrossrefPubMedGoogle Scholar